85-1456-97　Flk-1 Receptor Tyrosine Kinase, Mouse, Control Peptide (KDR, VEGFR2) 100ug　F4565-08D

特徴

• Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1 or fms-like tyrosine kinase 1), VEGFR-2 (flk-1 or fetal liver kinase-1/KDR or Kinase insert domain containing receptor), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo
• FLK-1 (Fetal-Liver Kinase 1; human homolog is KDR, Kinase insert domain containing receptor or VEGF-R2; mouse 1345 aa; rat 1343 aa, and human 1356), a putative receptor protein tyrosine kinase. FLK-1 belongs to the family of type-1 membrane protein. Human FLK-1 protein: 1-19 signal peptide, 20-1356 mature protein (20-764 extracellular domain, 765-789 TM, and 790-1356 cytoplasmic domain). FLK-1 Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. It is expressed in endothelial cells of developing embryo (1). It is also expressed at high levels in adult heart, lung, kidney, brain and skeletal muscle, but is also expressed at lower levels in most other adult tissues.
• Source:20aa peptide of mouse FLK1/VEGF-R2, conjugated to KLH
• Epitope Location:~C-terminal, Cytoplasmic domain
• Applications:Suitable for use in Antibody Blocking and ELISA. Not suitable for Western Blot. Other applications not tested.
• Recommended Dilutions:ELISA: 50-100ng control peptide/well
• Antibody Blocking: 5-10ug per 1ug F4565-08A
• Optimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.